Santhera Pharmaceuticals Holding AG
ISIN: CH0027148649 | Ticker: SANN | LEI: 54930035HAOFTTQH0U85
Country: Switzerland
We are focusing on the development of treatments for neuromuscular and pulmonary diseases that currently lack treatment options, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF).
We have dedicated more than a decade to researching potential treatments in our ongoing mission to make effective medicines available for these often overlooked, life-altering diseases. We are passionate about improving patients’ quality of life and our vision is to be a leader in providing treatments for rare diseases in these areas with high unmet medical needs.
2004
Served areaWorldwide
Headcount91
HeadquartersHohenrainstrasse 24, 4133 Pratteln – Switzerland
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 11.01.22 | None | Non-Executive member | Buy | CHF 42,600.00 |
| 10.01.22 | None | Executive member | Buy | CHF 14,420.00 |
| 05.01.22 | None | Executive member | Buy | CHF 37,000.00 |
CH0027148649
LEI54930035HAOFTTQH0U85
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.